“…In contrast to frontline therapy, the combination of zanubrutinib, another next‐generation BTK inhibitor, and obinutuzumab achieved an ORR of 92%, including 7 CRs (28%) in patients with relapsed/refractory CLL or small lymphocytic lymphoma after a median follow‐up of 29 months 10 . Within the heterogeneous population of the CLL2‐BIG trial, the combination of ibrutinib plus obinutuzumab with an optional bendamustine debulking yielded an ORR of 100% with 9.8% CR 11 . These reported CR rates are consistent with those presented here.…”